{
    "nctId": "NCT00975676",
    "briefTitle": "Study of Estrogen Levels in Premenopausal Women Who Have Undergone Surgery for Breast Cancer and Are Receiving Triptorelin and Tamoxifen Citrate or Exemestane on Clinical Trial IBCSG 24-02",
    "officialTitle": "A Substudy of the IBCSG 24-02/ SOFT Trial to Investigate Estrogen Suppression for Patients Participating in Arms B and C of the IBCSG 24-02/ SOFT Trial",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 123,
    "primaryOutcomeMeasure": "Estrogen Levels (Estradiol [E2], Estrone [E1], and Estrone Sulphate [E1S]) at Different Time Points During the First 4 Years of Treatment With Triptorelin (Trip) in Combination With Either Tamoxifen (T) or Exemestane (E), IBCSG 24-02 SOFT-EST Substudy",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically confirmed resected breast cancer\n* Concurrent enrollment on clinical trial IBCSG-2402 (SOFT trial) required\n\n  * Randomized to receive triptorelin in combination with either tamoxifen citrate or exemestane\n* Hormone receptor status:\n\n  * Estrogen receptor- and/or progesterone receptor-positive tumor\n\nPATIENT CHARACTERISTICS:\n\n* Premenopausal\n\nPRIOR CONCURRENT THERAPY:\n\n* See Disease Characteristics",
    "sex": "FEMALE",
    "minimumAge": "0 Years",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}